1. 4/2/2017
The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
Dial In:
Passcode: Cancer Centers   For Technical Support, call and choose option 3.
National Cancer Institute

2. The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
Tuesday, September 11, 2012
2:00 to 3:00 pm EDT
Moderator
Shannon Silkensen, Ph.D.
Program Director
Office of Cancer Centers
National Cancer Institute
National Institutes of Health
Bethesda, MD
Featured Presenters
Jeffrey D. White, M.D. Director, Office of Cancer Complementary and Alternative Medicine (OCCAM)
Division of Cancer Treatment and Diagnosis, NCI
Dan Xi, Ph.D.
Program Director, Office of Cancer Complementary and
Alternative Medicine (OCCAM)
Lorenzo Cohen, Ph.D.
Professor and Director of the Integrative Medicine Program
MD Anderson Cancer Center, Houston, TX

3. A Quick Guide to Your Screen
Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging the box that opens to the right side of your screen.

4. 4/2/2017
NCI’s Complementary and Alternative Medicine Activities: A Brief Overview
Cancer Centers Webinar September 11, Jeffrey D. White, M.D. Director, Office of Cancer Complementary and Alternative Medicine, NCI
National Cancer Institute

5. Terminology and Definitions
Complementary and Alternative Medicine (CAM)
“Medical and health care practices that are not an integral part of conventional (Western) medicine.” (National Center for Complementary and Alternative Medicine)
“…a broad set of health care practices that are not part of that country’s own tradition and are not integrated in the dominant health care system.” (World Health Organization)

6. Terminology and Definitions
Complementary and Alternative Medicine (CAM)
Complementary – Used in combination with conventional treatment
Alternative – Used instead of conventional treatment
Integrative Medicine
Combination of conventional (Western) medicine and components of other medical traditions or other unconventional modalities with sufficient evidence-based support.

7. Major Domains of Complementary and Alternative Medicine Research (NCI, OCCAM)
Alternative Medical Systems and some of their components (e.g. Traditional Chinese Medicine, Homeopathy, acupuncture)
Energy Therapy
Electromagnetic (e.g. electrochemotherapy)
Theoretical (e.g. Reiki, Qi gong)
Exercise
Western forms (e.g. aerobic, isometric)
Other (e.g. T’ai Chi, yoga)
Manipulative and Body-Based Therapies (Therapeutic massage, Osteopathy, Chiropractice)

8. Major Domains of Complementary and Alternative Medicine Research (NCI, OCCAM)
Mind-Body Interventions (e.g. hypnosis, imagery, relaxation therapy)
Nutritional Therapeutics (e.g. diet modification, specific foods, nutrients, bioactive food components)
Pharmacological and Biologically-based Therapies
Complex natural products (e.g. botanicals, extracts from marine animals [e.g. shark cartilage])
Off-label use of certain drugs not traditionally used as cancer therapies (e.g. naltrexone)
Spirituality and Spiritual Healing
Miscellaneous
Chronobiology and Chronotherapy
Things we capture in the definition which may be controversial:
Circadian rhythms, chronomodulated chemotherapy
Off label uses of certain drugs – e.g. Naltrexone
Unconventional approaches to the augmentation of chemotherapy effect – e.g. insulin potentiation therapy, nutrient supplementation or depletion
Diet as a primary or adjuvant therapy for cancer – e.g. Women’s Intervention Nutrition Study (WINS)
Psychoneuroimmunology
Potential Opportunities:
Things in use in other countries but not studied or rarely studied in the U.S. – e.g. beta glucans
Potential Approaches to Augment the Effect of Conventional Cancer Therapies – E.g. psychoneuroimmunology, exercise – chemotherapy or immune therapies
Vitamin C, intravenous, high-dose

9. Comparative analysis of CAM use by the U. S
Comparative analysis of CAM use by the U.S. Cancer and Non-Cancer populations*
Secondary analysis of the 2002 NHIS Survey
31,044 respondents
28,734 individuals without prior CA diagnosis
2,262 cancer survivors
461 diagnosed within the last 12 months
1786 diagnosed > 12 months prior
Results:
Cancer survivors use CAM more frequently than individuals without a cancer diagnosis (39.2% vs. 34.9%, p<0.001
*Fouladbakhsh JM, Strommel M. Journal of Complementary and Integrative Medicine 2008;5(1): Art. 19 (Epub)

10. NCI’s Annual Report on Complementary and Alternative Medicine 2010
PDF version is available on the OCCAM website (

11. NCI’s CAM Expenditures Fiscal Years 2003-2010
From: NCI’s Annual Report on Complementary and Alternative Medicine: Fiscal Year 2010, NIH Publication No , Feb. 2012

12. NCI’s Cancer CAM Portfolio FY2010
Overview
> 400 projects, approx. $114.4 million
Extramural - Grants, cooperative agreements and contracts
Diffusely represented throughout portfolios of the four grant making extramural divisions (DCB, DCCPS, DCP, DCTD) – Over 50 different PDs
Intramural (CCR and DCEG) – Projects and contracts
CCR = Center for Cancer Research; DCB = Div. of Cancer Biology; DCEG = Div. of Cancer Epidemiology and Genetics; DCP = Div. of Cancer Prevention; DCCPS = Div. of Cancer Control and Pop. Sciences; DCTD = Div. of Cancer Treatment and Diagnosis

13. NCI CAM Research Projects by CAM Category
From: NCI’s Annual Report on Complementary and Alternative Medicine: Fiscal Year 2010, NIH Publication No , Feb. 2012

14. Office of Cancer Complementary and Alternative Medicine, NCI
OCCAM established in October 1998
Director: Jeffrey D. White, M.D.
Organizational Location: Division of Cancer Treatment and Diagnosis (Formerly in the Office of the Director)
Physical Location: 6116 Executive Blvd., Suite 609, Bethesda, MD 20892
Program Areas:
Grant Portfolio
Communications and Outreach
Practice Assessment

15. Mission of OCCAM
To improve the quality of care of cancer patients, as well as those at risk for cancer and those recovering from cancer treatment, by contributing to the advancement of evidence-based CAM practice, the sciences that support it and to the availability of high-quality information for the healthcare community, researchers and the general public.

16. OCCAM’s International Research Collaborations

17. OCCAM supported NCI – Beijing Guang’anmen Hospital Traditional Chinese Medicine Study Project
The collaborative study of TCM Shen Qi Formula (SQF) - an extract from two herbs: Astragalus mongholicus Bge, and Panax notoginseng) - has found:
SQF has direct inhibitory effect on the proliferation of
mouse 4T1 mammary tumor cells.
The inhibitory effect of whole SQF extracts on mouse
4T1 tumor cell is greater than its individual major
ingredients or the combination of major ingredients.
SQF treatment up-regulated pro-apoptosis genes
(Bad and Apaf1), and down-regulated anti-apoptosis
gene Bcl2.

18. OCCAM supported NCI – Kunming Institute of Botany (KIB) Anti-cancer Agents Screening Project
Established collaboration in October 2008, an MOU was signed
between NCI and KIB.
Compounds from KIB were sent to NCI to start the anti-cancer
activity screening on NCI 60 human cancer cell lines in 2009.
Total of 58 compounds have been screened on NCI 60.
36 single concentration screening
11 compounds had 5 conc. Screening
None to animal testing
Molecular Targets Development Program has also investigated these compounds assays examining effects on specific cellular signaling pathways, such as TRAIL, AP-1, HIF-2

19. OCCAM supported NCI – Key Laboratory of Chemistry for Natural Products of Guizhou Anti-cancer Agents Screening Project
Established collaboration on anti-cancer agents screening in December 2009.
An MOU was singed between NCI and Key Lab of Chemistry for Natural Products (KLCNP) of Guizhou in March 2010.
More than 200 compounds from KLCNP of Guizhou were sent to NCI to start the anti-cancer activity screening on NCI 60 human cancer cell lines in 2010.
38 so far in one conc. testing and 3 on to 5 conc.
KLCNP of Guizhou also sent 150 regional-specific herbal extracts to NCI in 2011 for potential anti-cancer activity screening.

20. Communications and Outreach Program

21. Communications and Outreach Program
Promotes NCI CAM research activities, events, and initiatives
Develops print and online information products on cancer CAM for healthcare professionals and the general public, including the website:
NCI Annual Report on Complementary and Alternative Medicine
CAM PDQ support
Research/practitioner listserv for NCI CAM related events and news
Invited lecturers
NCI CAM News, our twice-yearly newsletter
Patient Education resources

22. 4/2/2017
National Cancer Institute

23. 4/2/2017
The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
Questions?
Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging the box that appears it to the right side of your screen.
Jeffrey D. White, M.D. Director, Office of Cancer Complementary and Alternative Medicine (OCCAM)
Division of Cancer Treatment and Diagnosis, NCI
Barbara A. Conley, MD has been Associate Director of the Cancer Diagnosis Program (CDP) in the NCI Division of Cancer Treatment and Diagnosis (DCTD)
National Cancer Institute

24. NCI Cancer CAM Funding Opportunities and Grant writing
Dan Xi, Ph.D.
Program Director
Office of Cancer Complementary and Alternative Medicine (OCCAM)
National Cancer Institute (NCI)
National Institutes of Health (NIH) (

25. Objectives
To share information about the OCCAM/NCI cancer CAM portfolio, funding opportunities and initiatives in cancer CAM research, as well as some aspects on strategies for grant writing

26. Research Grant Funding and Portfolio at OCCAM, NCI
Major Functions:
Analyze NCI cancer CAM portfolio
Identify gaps in existing cancer CAM research
Develop evidence-based scientific foundation of the field
Create and expand funding opportunities to stimulate high quality research in cancer CAM
Provide technical assistance to applicants
Manage grants of cancer CAM interventions for treatment
Coordinate the cancer CAM grant activities at NCI
Program Philosophy: Keep CAM research integrated within the relevant NCI scientific programs (e.g. prevention, symptom management and supportive care, survivorship and behavioral medicine etc.)

27. OCCAM’s Research Priorities
Identifying novel therapeutics in the pharmacopeia of traditional medical systems as defined by the World Health Organization
Using complementary approaches to improve the therapeutic ratio of standard and investigational anti-cancer therapies
Research on lifestyle modifications (e.g. diet, exercise, mind-body approaches) for their impact on cancer outcomes (e.g. response to conventional cancer therapy, survival)

28. Types of NIH Grant Funding Programs (http://grants. nih
The following represents some main types of grant funding programs in the cancer CAM research:
R01: NIH Research Project Grant Program (R01)
Used to support a discrete, specified, circumscribed research project
NIH's most commonly used grant program
No specific dollar limit unless specified in FOA
Advance permission required for $500K or more (direct costs) in any year
Generally awarded for 3 -5 years
NCI use NIH parent FOA: PA (
OCCAM Active Grant Portfolio (R01)

29. Types of NIH Grant Funding Programs
R21: NIH Exploratory/Developmental Research Grant Award (R21)
Encourages new, exploratory and developmental research projects by providing support for the early stages of project development. Sometimes used for pilot and feasibility studies.
Limited to up to two years of funding
Combined budget for direct costs for the two year project period usually may not exceed $275,000.
No preliminary data is generally required
See NCI specific PAR
R03 NIH Small Grant Program (R03):
Provides limited funding for a short period of time to support a variety of types of projects, including: pilot or feasibility studies, collection of preliminary data, secondary analysis of existing data, small, self-contained research projects, development of new research technology, etc.
Limited to two years of funding
Direct costs generally up to $50,000 per year
Not renewable
See NCI specific PAR

30. OCCAM Active Grant Portfolio 2011-2012 (R21)30

31. Other OCCAM Active Grant Portfolio 2011-2012 (P01 and R13)
P01: Research Program Project Grant
Support for integrated, multi-project research projects involving a number of independent investigators who share knowledge and common resources
Each project contributes or is directly related to the common theme of the total research effort, thus forming a system of research activities and projects directed toward a well-defined research program goal
See NCI specific FOA: PAR (
R13: NIH Support for Conferences and Scientific Meetings (R13 and U13)
Support for high quality conferences/scientific meetings that are relevant to NIH's scientific mission and to the public health
Requires advance permission from the funding IC
Foreign institutions are not eligible to apply
See NIH parent FOA: PA 31

32. Other OCCAM Active Grant Portfolio 2011-2012 (U01 and U19)
Cooperative Agreement (U Series) A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.

33. Grants Process At-a-Glance (http://grants. nih
Any successful project requires planning, development, implementation, and follow-through. Obtaining NIH funding for your research idea is no exception.  The Grants Process At-A-Glance Chart below provides an overview of the steps required for an application to proceed from application planning and submission through award and close out.  Look to the related resources for special guidance from NIH experts that can help maximize your understanding of the grants process and help you submit a successful grant application.

34. Grants Process At-a-Glance (continued)34

35. Funding Opportunity Announcements Related to Cancer CAM (http://www
NCI-wide Funding Opportunities *new* (R21 and R03)
OCCAM Participating Announcements
Behavioral/ Mind-Body
Diet, Nutrition & Physical Activity
Symptom Management
Survivorship *new*
Miscellaneous

36. Funding Opportunity Announcements Related to Cancer CAM
Specific Research Objectives: All areas of cancer research relevant to the mission of the NCI are appropriate for projects submitted in response to this FOA [for a list of extramural research funding programs at the NCI, go to Projects proposed in response to this FOA may involve basic, translational, clinical, and/or population research. Examples of relevant areas include but are not limited to studies of: cancer biology; cancer control; cancer diagnosis; cancer disparities; cancer prevention; and cancer treatment. 36

37. Funding Opportunity Announcements Related to Cancer CAM37

38. Funding Opportunity Announcements Related to Cancer CAM38

39. Funding Opportunity Announcements Related to Cancer CAM39

40. Grant Application Information (http://www. cancer
Research Priorities: -OCCAM Research Priorities; -NCI Research Priorities
Tips for Writing a Grant:
Strategies for Success: How to Write a Cancer CAM Grant (PDF): Reviews issues unique to CAM related research areas and provides tips to writing a cancer CAM grant
Expert Opinions on Methodology: Development of Cancer CAM Symptom Research (PDF): Identifies CAM research methodology challenges and proposes potential solutions to assist grant applicants with future cancer CAM research proposals
Grant Application and Review Process: web links to NCI and NIH
Information for Grantees
Research Policies
Frequently Asked Questions about Research (

41. Frequently Asked Questions about Grant Applications (http://www.cancer.gov/cam/research_faqs.html)
Where can I find information and guidance on preparing a grant application?
Preparing to submit a grant application can feel overwhelming. Here are some suggestions to avoid some of the common pitfalls of grant applications:
Have a clear project description without complexity
Set realistic and not overly ambitious specific aims
Create a clear conceptual model
Strive for a well-defined methodology
Note the validity and replicability of the project
Cite background studies and references
Discuss statistical expertise and provide a clear data analysis plan
Have a plan for quality assurance
Note the expertise of investigator teams
Additionally, please visit these NIH and NCI websites for more broad information about grant writing and submission.
NIH Office of Extramural Research Grant Writing Tips Sheets:
NCI Grant Application and Review Process

42. Frequently Asked Questions about Grant Applications (http://www.cancer.gov/cam/research_faqs.html)
What review group would best fit the proposed application? Applicants can search for matching review groups at the following link:
Can an applicant propose a study review group or IRG for their application? Below are some recommendations on how to write a cover letter to propose a specific study section for your application.
Read about CSR Study Sections at:
Identify an appropriate study section.
You can propose in your cover letter where your application appears to have the best fit.
You may suggest the inclusion of reviewers with specific scientific expertise.
You can indicate the name of the Program Director who has provided you with technical assistance with the Branch/Office.
Does NCI or OCCAM have a CAM-specific review Special Emphasis Group (SEP)? No. Applications are evaluated for scientific and technical merit by (an) appropriate scientific review group(s) in accordance with NIH peer review procedures ( and under the section of “Application Review Information” in the Funding Opportunity Announcement (FOA). Most of applications of CAM cancer research have been reviewed by Center for Scientific Review (CSR)

43. Thank You 43

44. 4/2/2017
National Cancer Institute

45. 4/2/2017
The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
Questions?
Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging the box that appears it to the right side of your screen.
Dan Xi, Ph.D.
Program Director, Office of Cancer Complementary and
Alternative Medicine (OCCAM)
Division of Cancer Treatment and Diagnosis, NCI
Barbara A. Conley, MD has been Associate Director of the Cancer Diagnosis Program (CDP) in the NCI Division of Cancer Treatment and Diagnosis (DCTD)
National Cancer Institute

46. Traditional Chinese Medicine and Other Research Opportunities in Integrative Oncology
Lorenzo Cohen, PhD
Director, Integrative Medicine Program

47. International Center of Traditional Chinese Medicine for Cancer
Lorenzo Cohen, Ph.D., Principal Investigator/Co-Director
Luming Liu, M.D., Co- Principal Investigator/Co-Director
Zhiqiang Meng, M.D., Ph.D., Deputy Director
R21 (CA108084, NCI)
U19 (CA121530, NCI)

48. Aims
Evaluate herbal/natural product treatments that target disease outcomes and treatment- and disease-related symptoms.
Determine the effects of acupuncture on specific clinical symptoms in patients with cancer.
Quantify the biobehavioral effects of qigong and other mind/body-based interventions.
Examining the reliability and validity of TCM diagnostic techniques.

49. International Center of Integrative Oncology (ICIO) Established September 2003

50. Cooperation 7 TCM Clinical Trials Staff training 2 Natural products
4 Acupuncture
1 Qigong

51. International Center of TCM for Cancer
Dr. Lorenzo Cohen,
Principal Investigator;
Co-Director
Dr. Luming Liu,
Co-Principal Investigator
Co-Director
Projects
Cores
Phase I and II Trials of HuaChanSu
Dr. Zhiqiang Meng,
Dr. David Chang
Project Leaders
Qigong
Dr. Zhen Chen,
Dr. Lorenzo Cohen
Project Leaders
Administrative
Dr. Lorenzo Cohen,
Dr. Luiming Liu
Core Leaders
Biostatistics
Dr. Lynn Palmer,
Dr. Genming Zhao
Core Leaders
HuaCanSu Preclinical Research
Dr. Peiying Yang,
Dr. Zhiqiang Meng,
Project Leaders
Acupuncture Xerostomia (Two Trials)
Dr. Zhiqing Meng,
Dr. Joseph Chiang
Project Leaders
Epidemiology
Dr. Qingyi Wei,
Dr. Zhen Chen
Core Leaders
Acupuncture Ileus
Dr. Zhiqing Meng,
Dr. Joseph Chiang
Project Leaders
Acupuncture K1
Dr. Luming Liu,
Dr. Joseph Chiang
Project Leaders
Research Steering Committee
Dr. Joseph Chiang Dr. Lynn Palmer
Dr. Kay Garcia Dr. Lorenzo Cohen
Dr. David Chang Dr. Luming Liu
Dr. Razelle Kurzrock Dr. Zhiqing Meng
Dr. Zhongxing Liao Dr. Zhen Chen
Dr. Peiying Yang Dr. Yehua Shen
Dr. Qingyi Wei Dr. Huiting Peng
Dr. Chaosu Hu

52. Preclinical Evaluation and Phase I and II Trial of HuaChanSu

53. Pilot Study of Hauchansu Patients with Hepatocellular Carcinoma, Nonsmall-Cell Lung Cancer, or Pancreatic Cancer

54. Examples of Acupuncture

55. Acupuncture
Acupuncture research for postoperative paralytic ileus after colorectal surgery (Meng et al., WJG, 2010)
Effects of acupoint electro-stimulation on preventing nausea and vomiting induced by cisplatin or oxaliplatin
Acupuncture for the prevention of radiation-Induced xerostomia (Meng et al., Cancer, 2011;
Meng et al., Euro J Cancer, 2012)

56. Ongoing Research Projects Acupuncture
Xerostomia treatment (CCOP; R01)
Xerostomia prevention (Multicenter R01)
Neuropathy – Compare twice weekly versus three-times weekly acupuncture (Institutional Research Grant)
Neuropathy – Evaluate electrical acupuncture and total treatments (Sister Institution Fund)
Ensure that we start to truly practice integrative medicine and not just provide disjointed services. 56

57. Ongoing Research Projects Mind-body
Mindfulness relaxation - general (CCOP)
Tibetan yoga- breast cancer (R01)
Tibetan sound meditation for chemobrain (R01 pending)
Hatha yoga during xrt for breast cancer (R01)
Qigong/Tai chi during xrt for rectal/prostate (R21)
Neurofeedback for peripheral neuropathy (ACS)
Guided meditation during breast biopsy
Ensure that we start to truly practice integrative medicine and not just provide disjointed services. 57

58. Natural Products are a Common Source of Chemotherapeutic Agents
Catharanthus roseus (Periwinkle)
Vinblastine
Taxus brevifolia (Yew Tree)
Paclitaxel
Camptotheca acuminata (Happy Tree)
Irinotecan
Podophyllum pelatum (Mayapple)
Etoposide

59. Natural Products Being Investigated in Dr
Natural Products Being Investigated in Dr. Peiying Yang’s Laboratory for Prevention and Treatment of Cancer
Fish Oil/EPA – Anti-inflammatory/COX-2 - Lung Cancer Prevention (R01)
Sweet Gum – PI3k/Akt/mTOR inhibitor – Prostate Cancer/HCC (R21 and Internal)
Nerium Oleander (Anvirzel & PBI) - Lung and Pancreatic cancer (CCOP and Sponsored Research Agreement)
Black cumin – Hepatocellular Carcinoma (Internal)
Toad skin extract (Huachansu or TSO) – Lymphoma, HCC and pancreatic cancer (Foundation and Sponsored Research Agreement)

60. Considerations Grantsmanship Study sections Program Officers
Pilot data
Feasibility
Significance
Study sections
Behavioral Medicine, Interventions and Outcomes (BMIO)
Mechanisms of Emotion, Stress and Health (MESH)
Chemo/Dietary Prevention (CDP)
Program Officers

61. Integrative Oncology Healthcare Professional Training Conference

62. 4/2/2017
The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
Questions?
Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging the box that appears it to the right side of your screen.
Lorenzo Cohen, Ph.D.
Professor and Director of the Integrative Medicine Program
MD Anderson Cancer Center, Houston, TX
National Cancer Institute

63. 4/2/2017
The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
Questions?
Please submit your question via the Q & A box on the right hand side of your screen. If you do not see the Q&A box, you can expand it by clicking the Q&A on the top navigation panel and dragging the box that appears it to the right side of your screen.
Jeffrey D. White, M.D. Director, Office of Cancer Complementary and Alternative Medicine (OCCAM)
Division of Cancer Treatment and Diagnosis, NCI
Dan Xi, Ph.D.
Program Director, Office of Cancer Complementary and
Alternative Medicine (OCCAM)
Lorenzo Cohen, Ph.D.
Professor and Director of the Integrative Medicine Program
MD Anderson Cancer Center, Houston, TX
National Cancer Institute

64. Disclosures Jeffrey D. White, M.D.: Financial disclosure.
Dan Xi, Ph.D.: Financial disclosure.
Lorenzo Cohen, Ph.D.: Financial disclosure. .

65. If you have further questions, please contact Elizabeth Austin
4/2/2017
The NCI Office of Cancer Centers Learning Series Complementary and Alternative Medicine Cancer Research and the National Cancer Institute
If you have further questions, please contact
Elizabeth Austin
This webinar was created by the Office of Cancer Centers in the National Cancer Institute
For information about the NCI’s Office of Cancer Complementary and Alternative Medicine, please visit
National Cancer Institute

66. NCI’s Cancer Information Service
4/2/2017
NCI’s Cancer Information Service
Offers comprehensive, research-based information in English and Spanish for patients, the public, health professionals, and cancer researchers
Phone: CANCER
Online Chat:
Web: and
Facebook: Facebook.com/cancer.gov
National Cancer Institute

67. 4/2/2017
National Cancer Institute